Drugs online research references
J Clin Psychiatry. 1983 May;44(5 Pt 2):163-9.
Bupropion's prophylactic efficacy in bipolar affective illness.
Shopsin B.
Three bipolar manic-depressive patients are described who, after responding to bupropion treatment for an acute depressive relapse, were maintained on the drug alone for a 1-year period, without recurrences of mania or depression. Discontinuation of medication was followed within 8 weeks by a manic or depressive recurrence in all three cases. Data are presented to suggest that bupropion probably exerted a prophylactic effect in preventing acute affective recurrences in these cases. This drug merits investigational attention as an alternative approach to current maintenance chemotherapy of recurrent affective disorder.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6406450&dopt=Abstract
word match zyban online literature
J Clin Psychiatry. 1983 May;44(5 Pt 2):60-2.
Preclinical toxicology of bupropion: an overview.
Tucker WE Jr.
In preclinical studies, the toxicologic profile of bupropion was determined in laboratory animals using exaggerated doses of drug in a variety of toxicologic assays. Under overdose conditions, clinical signs primarily referable to the central nervous system were seen in rats, mice, rabbits, and dogs. Very mild, reversible hepatotoxicity and anemia occurred in dogs with chronic dosing; lifetime administration in rats caused hepatocellular hypertrophy and focal hepatic hyperplasia. In both rats and dogs, there was an increase in liver weight related to hepatic enzyme induction. Appropriate tests indicated that bupropion is unlikely to have the potential to cause teratogenic, mutagenic, or carcinogenic effects in man.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6406465&dopt=Abstract
word match zyban online literature
J Clin Psychiatry. 1983 May;44(5 Pt 2):67-73.
The pharmacologic basis for therapeutic interest in bupropion.
Soroko FE, Maxwell RA.
Bupropion, a compound chemically dissimilar to tricyclic antidepressants and monoamine oxidase inhibitors, was found to be active in animal models that are predictive of antidepressant activity in man. Bupropion was also found to be pharmacologically and biochemically distinct from tricyclics and monoamine oxidase inhibitors. Furthermore, it lacked anticholinergic activity, was not sympathomimetic, and was at least 10-fold weaker as a cardiac depressant than the tricyclic antidepressants. It was concluded that bupropion would be better tolerated and safer in man than standard therapies and that its pharmacologic and biochemical profile held out the possibility of novel antidepressant actions.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6406467&dopt=Abstract
word match zyban online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||